ISSAQUAH, Wash.--(BUSINESS WIRE)--BaroPace Inc. announces its Phase I first-in-human trial of PressurePace TM, its patent-pending pacemaker control algorithm for the treatment of heart failure with ...

Please provide your email address to receive an email when new articles are posted on . A new expert consensus decision pathway stresses proper diagnosis and treatment of HF with preserved ejection ...

A key opinion leader provides insight into key HFpEF treatment strategies. This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, ...

CHICAGO — A new study has shown for the first time that a drug therapy can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction (HFpEF) and ...

Phenotyping in HFpEF aids in tailoring therapies, addressing comorbidities, and improving patient outcomes. Artificial intelligence models effectively diagnose HFpEF and predict mortality, enhancing ...

Please provide your email address to receive an email when new articles are posted on . Approximately 52% of patients with HF are categorized as those with a preserved ejection fraction.

Two new documents from the American College of Cardiology add to ongoing efforts to understand and properly manage the diverse patient population living with heart failure with preserved ejection ...

CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with ...

A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in ...

Evidence supporting medications that slow the heart rate (HR), notably beta-blockers, is overwhelming in heart failure (HF) with reduced ejection fraction. Underwhelming, however, is clinical trial ...